The Duke Cancer Institute is excited to announce the establishment of the Duke Sarcoma Center, a center of excellence for sarcoma treatment and research.

Spearheaded by orthopedic surgical oncologist and professor of Orthopedic Surgery and Pediatrics, Brian E. Brigman, MD, PhD, the Center is the natural outgrowth of DCI’s Sarcoma Disease Group — a program recognized for innovative personalized treatment grounded in state-of-the-art clinical and basic-science research and committed to training the next generation of sarcoma clinicians and scientists.

“Care for sarcoma patients has gone on for decades at Duke, but over the last 15 years or so, our specialized team has really grown into a national leader in this area. The Duke Sarcoma Center is a recognition of this accomplishment and a new beginning of even better care, research, and training at Duke,” says Brigman.

The multidisciplinary team is comprised of 35 specialists — physicians, physician assistants, nurses, and researchers across the disciplines of orthopedic surgery, surgical oncology, medical oncology, pediatric oncology, radiation oncology, radiology, neurosurgery, and pathology.

“We see more than 900 new patients in the Duke Cancer Institute’s Sarcoma Clinic per year across all specialties and are actively caring for more than 2000 patients. The majority are in active treatment or long-term-follow up or survivorship,” notes Brigman. “Sarcomas may be rare cancers, but they’re not rare for us. With our experience comes greater expertise.”

Sarcomas are cancers that affect the supporting tissue of the body. They can occur in bone, muscle, fat, or other tissues.

According to the American Cancer Society, about 3,910 new cases of cancer in the bones and joints and an estimated 13,190 new cases of soft tissue sarcoma will be diagnosed in adults and children this year. An estimated 2,100 people are expected to die from bone and joint sarcoma and 5,130 from soft tissue sarcoma.

That’s about 17,000-plus diagnoses and 7,000-plus deaths too many.

“Because they occur anywhere in the body, can affect people of any age, and have more than 100 different subtypes, they are very challenging to diagnose and cure,” Brigman explains. “This work requires a true team approach. There’s ample evidence to suggest that patient outcomes are better when they’re treated by an integrated subspecialized sarcoma team.”

Notably, in addition to adults, the Center treats a significant number of pediatric sarcoma patients. All five pediatric sarcoma specialists affiliated with the Center (Lars Wagner, MD, Corinne Linardic, MD, PhD, David Van Mater, MD, PhD, Michael Deel, MD and Susan Kreissman, MD) have clinics at Duke Children’s Health Center in Durham.

Diagnostic testing offered at the Center includes the use of chest X-ray, cross-axial imaging with MRI or CT imaging, nuclear medicine imaging with bone scan or PET imaging, and ultrasound- or CT scan-guided needle biopsies.

Patient cases are discussed weekly at a multidisciplinary sarcoma tumor board (a meeting of sarcoma specialists) where imaging and pathology are reviewed, and consensus is built around building the best treatment for an individual patient.

The team offers the latest treatment options to preserve healthy tissue and bone, including comprehensive limb-sparing surgeries to avoid the need for amputation, and radiation therapy that reduces potential damage to surrounding tissue and organs by targeting the tumor directly or the tumor site (before or following surgical removal). Radiation therapy modalities include intensity- modulated radiation therapy, intraoperative radiotherapy, and brachytherapy. Chemotherapy may also be deployed depending on the patient’s specific diagnosis, anticipated risks versus benefits, and other factors.

Clinical trials are also often an option for pediatric and adult patients with sarcomas.

“We have a strong record of developing innovative clinical trials and research studies at Duke and are dedicated to accelerating, into the clinic, those research discoveries with translational potential,” says associate professor of Medicine and practicing medical oncologist Richard F. Riedel, MD, the Duke Sarcoma Center’s associate director of Clinical Research. “Our goal is to try and have a clinical trial option for every patient who walks through the door.”

“Although our current treatments cure some patients with sarcomas, these therapies fail in too many patients. At the Duke Sarcoma Center, we have a critical mass of investigators funded by the NIH and foundations who are focused on understanding the mechanisms of sarcoma development, metastasis, and developing novel treatments for sarcomas,” says Kirsch. “Our goal is to not only make impactful discoveries in the lab but translate them to new treatments for sarcoma patients in the clinic.”

Some of the clinician-scientists and researchers affiliated with the Duke Sarcoma Center also play an active role in the DCI Comparative Oncology program, which leverages research and resources across species to ensure the development of new diagnostics and therapies for naturally occurring cancers, including bone and soft-tissue sarcomas.

Led by orthopedic surgical oncologist William Eward, DVM, MD — an expert in treating pediatric, adult, canine, and other mammalian sarcomas — Comparative Oncology brings together researchers, medical doctors, and veterinarians at Duke, NC State University's College of Veterinary Medicine, and the Triangle Veterinary Referral Hospital to defeat the common enemy of cancer.

Community engagement is an important pillar of the team’s mission.

This includes planned public symposia on sarcoma treatment and research and the traditional Strike Out for Sarcoma run/walk event, an annual event that brings together patients and families, friends and caregivers, survivors, providers, and the local community to raise awareness and research support for the program.

This article was updated on April 26, 2022, to update the number of Center members -- from 25 to 35.